InvestSMART

Biotron Limited (ASX: BIT) - Announcements

Current share price for BIT : $0.002 0.001 (100%)+

ASX company news and announcements for Biotron Limited (BIT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Biotron Limited (BIT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Biotron Limited (BIT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Biotron Limited (BIT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Prospectus 27 Oct 2022 9:01AM $0.045 $0.002 fallen by 95.56%
$6 Renounceable Issue 27 Oct 2022 8:59AM $0.045 $0.002 fallen by 95.56%
$6 Proposed issue of securities - BIT 27 Oct 2022 8:25AM $0.045 $0.002 fallen by 95.56%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 24 Oct 2022 8:57AM $0.049 $0.002 fallen by 95.92%
$6 Annual Report and Notice of Annual General Meeting 14 Oct 2022 11:08AM $0.050 $0.002 fallen by 96%
$6 Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited 4 Oct 2022 10:13AM $0.046 $0.002 fallen by 95.65%
$6 Bit225 Covid-19 Human Study Commenced 14 Sep 2022 9:39AM $0.057 $0.002 fallen by 96.46%
$6 BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited 23 Aug 2022 12:16PM $0.059 $0.002 fallen by 96.61%
$6 Appendix 4G and Corporate Governance Statement 19 Aug 2022 3:57PM $0.059 $0.002 fallen by 96.61%
$6 Full Year Statutory Accounts and Appendix 4E 19 Aug 2022 3:56PM $0.059 $0.002 fallen by 96.61%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2022 10:13AM $0.065 $0.002 fallen by 96.92%
$6 POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM 30 May 2022 9:54AM $0.100 $0.002 fallen by 98%
$6 BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS 2 May 2022 10:12AM $0.071 $0.002 fallen by 97.18%
$6 Quarterly Cash Flow Report Appendix 4C 26 Apr 2022 1:28PM $0.076 $0.002 fallen by 97.37%
$6 Quarterly Activities Report 26 Apr 2022 1:28PM $0.076 $0.002 fallen by 97.37%
$6 $1.56M R&D Rebate Received 5 Apr 2022 9:47AM $0.076 $0.002 fallen by 97.37%
$6 BIT225 Effectiveness Against COVID-19 in Animals 17 Mar 2022 11:09AM $0.066 $0.002 fallen by 96.97%
$6 Half Yearly Report and Accounts 23 Feb 2022 4:09PM $0.064 $0.002 fallen by 96.88%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2022 9:20AM $0.075 $0.002 fallen by 97.33%
$6 Quarterly Appendix 4C Cash Flow Report 28 Jan 2022 8:38AM $0.075 $0.002 fallen by 97.33%
$6 Update on Biotron HIV-1 And COVID-19 Programs 16 Dec 2021 11:53AM $0.084 $0.002 fallen by 97.62%
$6 Notification of cessation of securities - BIT 6 Dec 2021 10:59AM $0.085 $0.002 fallen by 97.65%
$6 BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS 25 Nov 2021 9:19AM $0.051 $0.002 fallen by 96.08%
$6 Results of Meeting 23 Nov 2021 12:07PM $0.052 $0.002 fallen by 96.15%
$6 Chairman's Address and Presentation to AGM 23 Nov 2021 11:25AM $0.052 $0.002 fallen by 96.15%

201 - 225 of 602 results

Page 9 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.